ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
Last trade$179.00
Day change-$2.875 (-1.58%)
Day range$175.87 – $182.25
Volume103,636
Market cap$4.55B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.55B
Price / earnings
75.39×
Price / book
2.08×
Price / sales
2.08×
EV / sales
2.47×
EV / EBITDA
14.38×
Profitability
Earnings per share
$2.41
Return on assets
1.53%
Return on equity
2.75%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.53×
Current ratio
2.37×
Quick ratio
1.19×
Cash ratio
0.59×
Cash flow
Price / cash flow
16.29×
Price / free cash flow
21.81×
Free cash flow
$208.6M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ICUI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$560.44M
$551.68M
$530.23M
$540.7M
$536.99M
$548.87M
$604.7M
$629.81M
Cost of revenue
$325.69M
$316.63M
$324M
$337.72M
$336.11M
$340.8M
$394.59M
$402.55M
Gross profit
$234.75M
$235.05M
$206.23M
$202.99M
$200.88M
$208.06M
$210.11M
$227.26M
Selling, general and administrative
$154.41M
$151.92M
$154.57M
$155.81M
$152.77M
$159.39M
$157.23M
$158.85M
Research and development
$21.75M
$22.7M
$21.28M
$21.09M
$21.25M
$21.87M
$23.29M
$22.36M
Total operating expenses
$182.43M
$195.93M
$192.65M
$197.35M
$187.16M
$197.48M
$197.22M
$189.57M
Operating income
$52.32M
$39.13M
$13.58M
$5.64M
$13.72M
$10.59M
$12.89M
$37.69M
Interest expense
-$15.24M
-$15.75M
-$16.49M
-$20.64M
-$19.81M
-$20.55M
-$22.03M
-$23.46M
Income before taxes
$36.18M
$23.14M
-$4.58M
-$15.9M
-$2.51M
$33.68M
-$10.91M
$8.22M
Income taxes
$7.19M
$7.07M
-$34.71M
-$2.65M
-$658K
$1.18M
$4.57M
$32.05M
Net income
$26.85M
$19.09M
$30.13M
-$15.73M
-$3.4M
$35.34M
-$15.48M
-$23.83M
Net income attributable to common shareholders
$26.85M
$19.09M
$30.13M
-$15.73M
-$3.4M
$35.34M
-$15.48M
-$23.83M
EBITDA
$108.19M
$110.04M
$80.41M
$76.92M
$77.66M
$76.47M
$79.03M
$100.46M
Basic earnings per share
$1.07
$0.76
$1.22
-$0.64
-$0.14
$1.43
-$0.63
-$0.97
Diluted earnings per share
$1.07
$0.76
$1.20
-$0.61
-$0.14
$1.43
-$0.63
-$0.97
Recent news
Company coverage with links to the original publishers.
ICU Medical reported quarterly earnings of $2.44 per share, beating consensus estimates of $2.14 and representing a 14.02% earnings surprise. Revenue of $556.22 million slightly exceeded expectations. The company has outperformed the S&P 500 by 8.7% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market. The Medical-Products industry ranks in the bottom 36% of Zacks industries.
ICU Medical reported Q3 2026 revenue of $556.22 million, up 4.3% year-over-year, beating consensus estimates by 0.55%. The company delivered an EPS of $2.44, significantly exceeding the consensus estimate of $2.14 by 14.02%. The stock has gained 10.6% over the past month and currently holds a Zacks Rank #3 (Hold) rating.
The Medical Products industry faces moderate growth prospects with resilient healthcare demand offset by tariff pressures and manufacturing costs. ICU Medical shows strong momentum in infusion systems with improving earnings, Neogen benefits from commercial execution improvements in food and animal safety, while Trulieve Cannabis expects growth acceleration from new markets like Georgia and Texas despite Florida seasonal softness.
ResearchAndMarkets.com released a comprehensive market report on China's airway management sector, covering historical data from 2018 and forecasts through 2033. The report segments the market into Airway Management Tubes and Intubation Accessories, providing revenue, volume, and pricing analysis. It includes 2025 company share data and profiles of key competitors to support strategic planning and investment decisions in this growing medical device market.
ICU Medical CFO Brian Bonnell sold 9,307 shares on August 31, 2026, through a pre-planned Rule 10b5-1 trading plan established in June 2026. The sale, valued at $1.6 million, is not considered a red flag as it was scheduled in advance and Bonnell retains 62,443 shares worth $10.8 million. Analysts remain bullish on the stock with an 88% buy rating and a median price target of $195.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.